Angiotensin Receptor Blockers : Current Status and Future ProspectsRAM, C. Venkata S.The American journal of medicine. 2008, Vol 121, Num 8, pp 656-663, issn 0002-9343, 8 p.Article

Angiotensin II-receptor blocker dosages : How high should we go?DÜSING, R.International journal of clinical practice (Esher). 2006, Vol 60, Num 2, pp 179-183, issn 1368-5031, 5 p.Article

Increased Capillary Branching Contributes to Angiotensin Type 1 Receptor Blocker (ARB)―Induced Regression of SclerosisSCRUGGS, Benjamin S; YIQIN ZUO; DONNERT, Ellen et al.The American journal of pathology. 2011, Vol 178, Num 4, pp 1891-1898, issn 0002-9440, 8 p.Article

LES INHIBITEURS COMPETITIFS DE L'ANGIOTENSINE IICHAMONTIN B; SALVADOR M; GUITTARD J et al.1980; THERAPIE; ISSN 0040-5957; FRA; DA. 1980; VOL. 35; NO 5; PP. 637-640; BIBL. 18 REF.Article

2nd international forum on angiotensin II receptor antagonism (Monte-Carlo, January 24-26 2001, abstracts)International forum on angiotensin II receptor antagonism. 2001, 44 p.Conference Proceedings

Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancerVOLPE, Massimo; AZIZI, Michel; JAN DANSER, A. H et al.European heart journal. 2011, Vol 32, Num 1, pp 19-22, issn 0195-668X, 4 p.Article

Angiotensin II can induce and potentiate shape change in human platelets : effect of losartanJAGROOP, I. A; MIKHAILIDIS, D. P.Journal of human hypertension. 2000, Vol 14, Num 9, pp 581-585, issn 0950-9240Article

A cyclic angiotensin antagonist: [1,8-cysteine]angiotensin IIMATSOUKAS, J. M; SCANLON, M. N; MOORE, G. J et al.Journal of medicinal chemistry (Print). 1984, Vol 27, Num 3, pp 404-406, issn 0022-2623Article

High-Affinity Interaction of Sartans with H⁺/Peptide TransportersKNÜTTER, Ilka; KOTTRA, Gabor; FISCHER, Wiebke et al.Drug metabolism and disposition. 2009, Vol 37, Num 1, pp 143-149, issn 0090-9556, 7 p.Article

SYSTEMIC HEMODYNAMICS AND HORMONAL RESPONSES DURING ANGIOTENSIN II BLOCKADE WITH SARALASINROOS JC; GEYSKES GG; BOER P et al.1981; J. CARDIOVASC. PHARMACOL.; ISSN 0160-2446; USA; DA. 1981; VOL. 3; NO 5; PP. 1106-1115; BIBL. 28 REF.Article

THE INFLUENCE OF SARALA ANGIOTENSIN II (SARALASIN) ON PLASMA ALDOSTERONE IN HYPERTENSIVE PATIENTSDONKER AJM; VAN HOOGDALEM P; PRATT JJ et al.1979; ACTA MED. SCAND.; SWE; DA. 1979; VOL. 205; NO 3; PP. 207-212; BIBL. 21 REF.Article

INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM. A NEW APPROACH TO THE THERAPY OF HYPERTENSIONONDETTI MA; CUSHMAN DW.1981; J. MED. CHEM.; ISSN 0022-2623; USA; DA. 1981; VOL. 24; NO 4; PP. 355-361; BIBL. 61 REF.Article

ORGAN SELECTIVE ANGIOTENSIN ANTAGONISTS: SARCOSYL¹-CYSTEINYL (S-METHYL)⁸-ANGIOTENSIN IFREER RJ; SUTHERLAND JC JR; DAY AR et al.1980; EUROP. J. PHARMACOL.; NLD; DA. 1980; VOL. 65; NO 4; PP. 349-354; BIBL. 18 REF.Article

SARALASINA ED IPERTENSIONE ARTERIOSA A BASSA RENINEMIA = SARALASINE ET HYPERTENSION ARTERIELLE AVEC RENINEMIE BASSEFRISINA N; BUEMI M; LASCO A et al.1980; BOLL. SOC. ITAL. BIOL. SPER.; ITA; DA. 1980; VOL. 56; NO 13; PP. 1367-1373; ABS. ENG; BIBL. 14 REF.Article

A Review of the Use of Angiotensin Receptor Blockers for the Prevention of Cardiovascular Events in Patients with Essential Hypertension Without Compelling IndicationsZAIKEN, Kathy; HUDD, Timothy R; CHENG, Judy Wm et al.The Annals of pharmacotherapy. 2013, Vol 47, Num 5, pp 686-693, issn 1060-0280, 8 p.Article

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertensionRITTER, J. M.BMJ (Overseas and retired doctors ed.). 2011, Vol 342, Num 7802, pp 868-873, issn 1759-2151, 6 p.Article

Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in IrelandWAN D ADNAN, Wan A. H; ZAHARAN, Nur L; BENNETT, Kathleen et al.British journal of clinical pharmacology. 2011, Vol 71, Num 3, pp 458-466, issn 0306-5251, 9 p.Article

Sartans et risque de cancerBABAI, Samy; BROCVIELLE, Hélène; LEBELLER, Christine et al.Médecine (Montrouge). 2010, Vol 6, Num 9, issn 1777-2044, p. 405Article

Prevention of dementia by ACE inhibitors and angiotensin receptor blockers ― potential but not provenTODD, S; MCGUINNESS, B; PASSMORE, A. P et al.International journal of clinical practice (Esher). 2010, Vol 64, Num 12, pp 1595-1598, issn 1368-5031, 4 p.Article

Angioedema and AT1 receptor blockers: Proceed with caution. Authors' replyMACLEAN, James A; HANNAWAY, Paul J; GAVRAS, Haralambos et al.Archives of internal medicine (1960). 2003, Vol 163, Num 12, pp 1488-1489, issn 0003-9926, 2 p.Article

Étude de la tolérance du valsartan en cardiologie de ville chez 3197 hypertendus (étude VALSE) = Evaluation of the safety and efficacy of valsartan in office practice in 3 197 hypertensive patients (the Valse study)GHANNAD, E; FRANCILLON, A; VAILLANT, J et al.Annales de cardiologie et d'angéiologie (Paris). 2000, Vol 49, Num 1, pp 13-20, issn 0003-3928Article

Antagonistes de l'angiotensine II : une voie prometteuse : Nouvelles perspectives dans la prise en charge médicamenteuse des insuffisants cardiaques = Angiotensin II antagonist in heart failureCOHEN-SOLAL, A.Archives des maladies du coeur et des vaisseaux. Pratique. 2000, Num JUN, pp 10-11, issn 1261-694X, NSConference Paper

Quelles sont les indications des antagonistes des récepteurs de l'angiotensine II ? = Angiotensin II antagonist chemotherapyLA BATIDE ALANORE, A; AZIZI, M.Concours médical (Paris). 1999, Vol 121, Num 14, pp 1063-1067, issn 0010-5309Article

Effect of losartan on human platelet activationGUERRA-CUESTA, J. I; MONTON, M; LOPEZ-FARRE, A et al.Journal of hypertension. 1999, Vol 17, Num 3, pp 447-452, issn 0263-6352Article

Le médicament du mois : L'irbésartan (Aprovel®) = Irbesartan (Aprovel®)KULBERTUS, H.RMLG. Revue médicale de Liège. 1999, Vol 54, Num 2, pp 125-127, issn 0370-629XArticle